cBIN1 Therapy Offers a New Path to Recovering Heart Function
Heart failure remains one of the most challenging cardiovascular syndromes to treat. Current therapies can reduce strain on the heart, improve symptoms, and slow disease progression, but many patients continue to experience worsening heart function over time. Presently, there is no cure for heart failure.
Researchers at the CVRTI are advancing a new therapeutic strategy focused on cardiac bridging integrator 1, or cBIN1, a protein that helps recover the internal architecture of heart muscle cells. In heart failure, cBIN1 levels are reduced, and the loss of this organizing protein contributes to impaired calcium handling, weakened contractions, and progressive structural remodeling of the heart.
The goal of cBIN1 gene therapy, now known as TLT-101, is to restore this critical protein in heart muscle cells and help failing hearts recover their structure and function. Remarkably, after one dose of TLT-101, our investigators are finding that heart failure can be reversed. This presents, for the first time, an opportunity for heart failure to be cured.
How cBIN1 Gene Delivery Restores Heart Muscle Cell Organization
cBIN1 gene therapy is designed to deliver the human cardiac BIN1 gene to heart muscle cells. The therapy uses an adeno-associated viral vector, a delivery system commonly used in gene therapy, to carry the genetic instructions for producing more cBIN1.
Unlike medications that primarily target blood pressure, fluid balance, heart rate, or neurohormonal stress, TLT-101 is designed to act directly within cardiomyocytes, which are the muscle cells responsible for the heart’s pumping action. By restoring cBIN1 expression, the therapy aims to repair the microscopic organization of the heart cell, specifically restoring structures involved in calcium signaling and contraction. Once cardiomyocyte organization is restored, cardiac function is then restored as well, and the cardiomyocytes start producing their own copies of cBIN1 again.
Non-Ischemic Dilated Cardiomyopathy Is the Initial Clinical Application for TLT-101
The initial clinical focus for cBIN1 gene therapy is heart failure caused by non-ischemic dilated cardiomyopathy, a condition in which the heart becomes enlarged and weakened for reasons not primarily due to blocked coronary arteries.
In this form of heart failure, the heart muscle progressively loses its ability to pump blood efficiently. Patients may experience fatigue, shortness of breath, fluid retention, reduced exercise capacity, recurrent hospitalization, and, in advanced cases, the need for mechanical circulatory support or heart transplantation.
CVRTI and TikkunLev Prepare TLT-101 for Regulatory Submission
CVRTI is working in partnership with TikkunLev Therapeutics to advance TLT-101 from academic discovery toward clinical development. This collaboration brings together CVRTI’s expertise in cardiovascular biology, translational cardiology, and heart failure research with TikkunLev’s focus on developing TLT-101 for clinical testing.
Pending regulatory approval, CVRTI is planning for an initial clinical trial to initiate in early 2027. This trial will assess TLT-101 safety, and early signals of biological and cardiac functional effect in patients with heart failure.
cBIN1 gene therapy remains investigational. It is not currently an approved treatment, and its safety and effectiveness in humans must be established through clinical trials.
